We demonstrated that SOX2 overexpression leads to tumor chemoresistance in osteosarcoma tumors.43 Our immunohistochemical results revealed higher SOX2 expression in chemotherapy-resistant osteosarcoma patients compared to chemotherapy-sensitive patients, suggesting that combining AKT inhibitor with chemotherapy may benefit treatment. Here, AKT1 is linked to osteosarcoma.